MSB 0.61% $4.91 mesoblast limited

Is this also not an important part of the report?: While...

  1. 406 Posts.
    lightbulb Created with Sketch. 116
    Is this also not an important part of the report?:

    While remestemcel-L and other MSC-based investigational products have demonstrated apparent immunomodulatory effects in in vitro experiments, the ability of remestemcel-L to reduce inflammation as measured by inflammatory biomarkers in humans receiving the product has not been demonstrated. SR-aGVHD is thought to be an immune-mediated disorder but its etiology is complex and many cell types are likely to be involved in its pathogenesis. Therefore, any efficacy remestemcel-L might have in treating this disease is not sufficient to demonstrate the product’s mechanism of action.
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $2.880B
Open High Low Value Volume
$4.96 $5.00 $4.90 $27.35M 5.546M

Buyers (Bids)

No. Vol. Price($)
35 132759 $4.90

Sellers (Offers)

Price($) Vol. No.
$4.92 26502 3
View Market Depth
Last trade - 16.10pm 25/09/2020 (20 minute delay) ?
-0.030 ( 0.87 %)
Open High Low Volume
$4.96 $5.00 $4.89 1281491
Last updated 15.59pm 25/09/2020 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.